Revogenex Ireland Ltd

Insys Therapeutics, Inc.

Nortic Holdings Inc.

Insys Development Company, Inc.

Acasti Pharma U.s., Inc.

Other

Insys Pharma, Inc.

Grace Therapeutics Inc.

Btcp Pharma, LLC

Grace Therapeutics U.s., Inc.

S George Kottayil

Venkat R Goskonda

Zhongyuan Zhu

Linet Kattookaran

Prasanna Sunthankar

Neha Parikh

Vimal Kavuru

Amresh Kumar

Kamalkishore Pati

Jeffrey Ping

Robert E Dudley

Jeffrey H Ping

Olivier Palatchi

Neha N Parikh

A method of providing an IV nimodipine infusion regimen using a solubilized nimodipine solution suitable for IV administration is disclosed. The IV nimodipine infusion regimen provides a constant infusion rate over the (entire) 24 hour period supplemented with higher infusions of nimodipine at set intervals to duplicate the 24 hour AUC and Cof an oral nimodipine dose.

Nimodipine parenteral administration

A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.

Stable nimodipine parenteral formulation

A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.

Therapeutic composition of intranasal lidocaine

A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.

A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient.

Betamethasone oral spray formulation and method of use to treat ataxia

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

Sublingual fentanyl spray

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.

Intravenous administration of tramadol

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

Growing community of inventors

West Windsor, NJ, United States of America

S George Kottayil